The purpose of this study was to estimate the prevalence and incidence of new diagnoses of attention-deficit/hyperactivity disorder (ADHD) and assess drug treatment of ADHD in the 3–17 year age group in Germany.
Method:
We analysed data from the German Pharmacoepidemiological Research Database (GePaRD) for the years 2004–2006. The GePaRD includes claim records of 14,000,000 members of four statutory health insurances, representing 17% of the German population. The assessment of ADHD diagnoses was based on International Classification of Diseases version 10 (ICD-10) codes in outpatient and hospital data.
Results:
In 2005, the age-standardized prevalence and incidence of new diagnoses were 2.5% and 9/1000 person-years, respectively. Both measures were 3–4 times higher for males than for females. Incidence of new ADHD diagnoses increased linearly up to the age of 8 years for boys and 9 years for girls and decreased abruptly thereafter. In the calendar quarter of the initial ADHD diagnosis, 9.4% (95% confidence interval [CI] 8.9–9.8%) received methylphenidate or atomoxetine and 36.8% (95% CI 36.1–37.6%) received at least one prescription of either drug within the first year. Initiation of drug treatment and choice of drug were similar for both sexes.
Conclusions:
ADHD is a common condition among children and youth in Germany. There are substantial differences by sex in the prevalence and incidence of new ADHD diagnoses, but only a small difference in drug treatment among those diagnosed with ADHD. A relatively low percentage of children receives drug treatment in the first year after the initial diagnosis of ADHD.
Get full access to this article
View all access options for this article.
References
1.
AdlerLD, NierenbergAA. Review of medication adherence in children and adults with ADHD. Postgrad Med, 122:184–191. 2010.
2.
AhrensW, HagemeierC, MühlbauerB, PigeotI, PuntmannI, ReinekeA, SteinbachM, TimmJ. Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study. Pharmacoepidemiol Drug Saf, 16:1298–1307. 2007.
3.
BanaschewskiT, BeckerK, ScheragS, FrankeB, CoghillD. Molecular genetics of attention-deficit/hyperactivity disorder: An overview. Eur Child Adolesc Psychiatry, 19:237–257. 2010.
4.
BanaschewskiT, HollisC, OosterlaanJ, RoeyersH, RubiaK, WillcuttE, TaylorE. Towards an understanding of unique and shared pathways in the psychopathophysiology of ADHD. Dev Sci, 8:132–140. 2005.
5.
BaumgaertelA, WolraichML, DietrichM. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry, 34:629–638. 1995.
6.
BehrS, AndersohnF, GarbeE. Risk of intracerebral hemorrhage associated with phenprocoumon exposure: A nested case–control study in a large population-based German database. Pharmacoepidemiol Drug Saf, 19:722–730. 2010.
7.
BellAS. A critical review of ADHD diagnostic criteria: What to address in the DSM-V. J Atten Disord, 15:3–10. 2011.
8.
BiedermanJ, FaraoneS, MilbergerS, CurtisS, ChenL, MarrsA, OuelletteC, MooreP, SpencerT. Predictors of persistence and remission of ADHD into adolescence: Results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry, 35:343–351. 1996.
BiedermanJ, PettyCR, EvansM, SmallJ, FaraoneSV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res, 177:299–304. 2010.
11.
CastellanosFX, LeePP, SharpW, JeffriesNO, GreensteinDK, ClasenLS, BlumenthalJD, JamesRS, EbensCL, WalterJM, ZijdenbosA, EvansAC, GieddJN, RapoportJL. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA, 288:1740–1748. 2002.
12.
DopfnerM, BreuerD, WilleN, ErhartM, Ravens–SiebererU. How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample—results of the BELLA study. Eur Child Adolesc Psychiatry17 Suppl1:59–70. 2008.
13.
FaberA, KalverdijkLJ, de Jong–van den BergLT, HugtenburgJG, MinderaaRB, TobiH. Parents report on stimulant-treated children in the Netherlands: Initiation of treatment and follow-up care. J Child Adolesc Psychopharmacol, 16:432–440. 2006.
FaraoneSV, BiedermanJ, MickE. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med, 36:159–165. 2006.
16.
FultonBD, SchefflerRM, HinshawSP, LevineP, StoneS, BrownTT, ModrekS. National variation of ADHD diagnostic prevalence and medication use: health care providers and education policies. Psychiatr Serv, 60:1075–1083. 2009.
17.
GarbeE, SulingM, KlossS, LindemannC, SchmidU. Linkage of mother–baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf, 20:258–264. 2011.
18.
Gemeinsamer Bundesausschuss. Decision of the Federal Joint Committee (G-BA) concerning a modification of the drug guideline: Appendix III Issue 44 Stimulants [in German]Dtsch Arztebl, 46:A1762. 2011.
19.
Gortz–DortenA, DopfnerM. Attention deficit/hyperactive disorders in children and adolescents as assessed by parents [in German]Z Kinder Jugendpsychiatr Psychother, 37:183–194. 2009.
20.
HabelLA, SchaeferCA, LevineP, BhatAK, ElliottG. Treatment with stimulants among youths in a large California health plan. J Child Adolesc Psychopharmacol, 15:62–67. 2005.
21.
HussM, HollingH, KurthBM, SchlackR. How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS)Eur Child Adolesc Psychiatry17 Suppl1:52–58. 2008.
22.
JanhsenK. Pills for Fidgety Philip [in German]GlaeskeGJK. GEK-Medication-Report 2007. Analysis results of GEK-data from the years 2005–2006 [in German]St. Augustin: Asgard-Verlag, 2007; 226–44.
23.
KesslerRC, AdlerLA, BarkleyR, BiedermanJ, ConnersCK, FaraoneSV, GreenhillLL, JaegerS, SecnikK, SpencerT, UstunTB, ZaslavskyAM. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: Results from the national comorbidity survey replication. Biol Psychiatry, 57:1442–1451. 2005.
24.
KielingC, KielingRR, RohdeLA, FrickPJ, MoffittT, NiggJT, TannockR, CastellanosFX. The age at onset of attention deficit hyperactivity disorder. Am J Psychiatry, 167:14–16. 2010.
25.
KosterI, SchubertI, DopfnerM, AdamC, IhleP, LehmkuhlG. Children and adolescents with hyperkinetic disorder. Frequency of the claims diagnosis in primary care based on the data of a regional Statutory Health Insurance Sample—Versichertenstichprobe AOK Hessen/KV Hessen (1998–2001) [in German]. Z Kinder Jugendpsychiatr Psychother, 32:157–166. 2004.
26.
KrautAA, SchinkT, Schulze–RathR, MikolajczykRT, GarbeE. Incidence of anogenital warts in Germany: A population-based cohort study. BMC Infect Dis, 10:360. 2010.
27.
KuntsiJ, WoodAC, RijsdijkF, JohnsonKA, AndreouP, AlbrechtB, Arias–VasquezA, BuitelaarJK, McLoughlinG, RommelseNN, SergeantJA, Sonuga–BarkeEJ, UebelH, van der MeereJJ, BanaschewskiT, GillM, ManorI, MirandaA, MulasF, OadesRD, RoeyersH, RothenbergerA, SteinhausenHC, FaraoneSV, AshersonP. Separation of cognitive impairments in attention-deficit/hyperactivity disorder into 2 familial factors. Arch Gen Psychiatry, 67:1159–1167. 2010.
28.
MannuzzaS, KleinRG, BesslerA, MalloyP, LaPadulaM. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry, 155:493–498. 1998.
PigeotI, AhrensW, ForaitaR, JahnI, PohlabelnH. Sample selection and outcome evaluation in primary prevention. J Publ Health, 15:93–99. 2007.
31.
PigeotI, AhrensW. Establishment of a pharmacoepidemiological database in Germany: Methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf, 17:215–223. 2008.
32.
PolanczykG, CaspiA, HoutsR, KollinsSH, RohdeLA, MoffittTE. Implications of extending the ADHD age-of-onset criterion to age 12: Results from a prospectively studied birth cohort. J Am Acad Child Adolesc Psychiatry, 49:210–216. 2010.
33.
PolanczykG, de LimaMS, HortaBL, BiedermanJ, RohdeLA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry, 164:942–948. 2007.
34.
PolanczykG, RohdeLA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry, 20:386–392. 2007.
35.
RobertsRE, RobertsCR, ChanW. One-year incidence of psychiatric disorders and associated risk factors among adolescents in the community. J Child Psychol Psychiatry, 50:405–415. 2009.
36.
RubiaK, SmithAB, BrammerMJ, TaylorE. Temporal lobe dysfunction in medication-naive boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability. Biol Psychiatry, 62:999–1006. 2007.
37.
SchinkT, BehrS, GarbeE. External validation of prescription data of non-steroidal anti-inflammatory drugs using the ‘Arzneiverordnungsreport’[in German]Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS), 2009(abstract).
38.
SchlackR, HollingH, KurthBM, HussM. The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 50:827–835. 2007.
39.
SchlanderM, SchwarzO, RothenbergerA, RoessnerV. Tic disorders: Administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample. Eur Psychiatry, 26:370–374. 2011.
40.
SchlanderM, SchwarzO, TrottGE, ViapianoM, BonauerN. Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision. Eur Child Adolesc Psychiatry, 16:430–438. 2007.
Schmidt–TroschkeSO, OstermannT, MelcherD, SchusterR, ErbenCM, MatthiessenPF. The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions [in German]Gesundheitswesen, 66:387–392. 2004.
43.
SchubertI, KösterI, AdamC, IhleP, DöpfnerM, LehmkuhlG. Prescriptions of psychotropic drugs for children and adolescents with the indication ‘hyperkinetic conduct disorder’ [in German]Z Gesundh Wiss, 11:306–324. 2003.
44.
SchubertI, KosterI, LehmkuhlG. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int, 107:615–621. 2010
45.
ShawP, EckstrandK, SharpW, BlumenthalJ, LerchJP, GreensteinD, ClasenL, EvansA, GieddJ, RapoportJL. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A, 104:19,649–19,654. 2007.
46.
SkountiM, PhilalithisA, GalanakisE. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr, 166:117–123. 2007.
47.
SurmanCB, AdamsonJJ, PettyC, BiedermanJ, KenealyDC, LevineM, MickE, FaraoneSV. Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: Evidence from a large controlled study. J Clin Psychiatry, 70:1523–1529. 2009.
48.
van den BanE, SouvereinP, SwaabH, van EngelandH, HeerdinkR, EgbertsT. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001–2006. J Child Adolesc Psychopharmacol, 20:55–61. 2010.
49.
VisserSN, BitskoRH, DanielsonML, PerouR, BlumbergSJ. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMRW Morbid Mortal Wkly Rep, 59:1439–1443. 2010.
50.
WeissG, HechtmanL, MilroyT, PerlmanT. Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry, 24:211–220. 1985.
51.
WitthöftJ, KoglinU, PetermannF. Comorbidity of aggressive behaviour and ADHD [in German]Kindh Entwickl, 19:218–227. 2010.
52.
WolffC. AKTIV-study. ADHD in children – therapy, treatment situation in Germany in German]Jahrestagung des BKJPP, 20116-8-2008. (abstract).
53.
WongIC, AshersonP, BilbowA, CliffordS, CoghillD, DeSoysaR, HollisC, McCarthyS, MurrayM, PlannerC, PottsL, SayalK, TaylorE. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)–a pharmacoepidemiological and qualitative study. Health Technol Assess, 13:1–120. 2009.
54.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization, 1993.
